1 BTC
=
- USD
REGENXBIO Inc.
As of May 30, 2026 at 24:05 UTC
Chart
About REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Market Statistics
Trading Metrics
How to Buy RGNX
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy RGNX
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesREGENXBIO Inc. (NASDAQ: RGNX) faces a class action lawsuit for securities violations. The company allegedly made false and misleading statements about the safety and efficacy of its RGX-111 product candidate while concealing adverse information from investors. The FDA placed a clinical hold on RGX-111 after a clinical trial participant developed a tumor. Shareholders who purchased shares between February 9, 2022 and January 27, 2026 are encouraged to contact DJS Law Group regarding potential recovery.
Pomerantz Law Firm has filed class action lawsuits against REGENXBIO Inc., AMC Entertainment Holdings, Inc., and Upstart Holdings, Inc. for alleged securities fraud and unlawful business practices. The REGENXBIO lawsuit was triggered by an FDA clinical hold on its gene therapy candidates RGX-111 and RGX-121, which caused the stock to fall 17.9% on January 28, 2026. Investors with losses are urged to contact the firm by the April 14, 2026 deadline to potentially serve as lead plaintiff.
Pomerantz Law Firm has filed class action lawsuits against AMC Entertainment Holdings, REGENXBIO Inc., and Upstart Holdings, alleging securities fraud and unlawful business practices. The AMC lawsuit specifically concerns APE preferred equity unit holders who were excluded from a special dividend following conversion to common stock due to an undisclosed loophole in the Certificate of Designations. Investors have until April 20, 2026, to request Lead Plaintiff status.
REGENXBIO investors can file a class action lawsuit for securities purchased between February 9, 2022 and January 27, 2026. The lawsuit alleges the company made false statements about the safety and efficacy of its RGX-111 gene therapy. On January 28, 2026, REGENXBIO announced the FDA placed a clinical hold on RGX-111 after an intraventricular CNS tumor was found in a trial participant, causing the stock to fall nearly 18%.
Rosen Law Firm is reminding REGENXBIO investors who purchased securities between February 9, 2022 and January 27, 2026 of the April 14, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that REGENXBIO made false and misleading statements about the efficacy and safety of its RGX-111 gene therapy trial while providing overwhelmingly positive public assertions, resulting in investor damages.